CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31

CASTLE BIOSCIENCES INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$32.16+0.20 (+0.64%)

Close on Oct 19, 2026

Market cap: $977.78M
P/E (TTM): –
Dividend yield: 0.00%

CASTLE BIOSCIENCES INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31
Revenue	357	340	344	344	346	347	332	312	288	251	220	192	168	152	137	124	110	98	94	86	78	68	63	63	63	61	52	46	35	28	23
Cost of Revenue	81	75	71	69	66	63	60	56	52	49	45	42	40	36	32	27	23	19	16	14	12	10	9.69	9.02	8.26	8.10	7.31	6.67	6.31	5.64	5.30
Gross Profit	276	265	273	275	280	284	272	255	235	202	175	150	128	116	105	97	87	79	78	72	66	58	53	54	54	52	45	39	28	22	17
Research & Development	55	54	52	50	49	51	52	53	54	53	54	52	50	49	45	43	40	34	30	25	20	16	13	12	10	8.90	7.39	5.36	5.14	4.99	4.85
Selling, General & Admin	244	236	229	223	217	210	200	194	188	182	180	174	166	159	143	130	116	99	87	77	66	55	48	43	38	35	30	24	21	18	16
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	44	37	30	26	23	21
Operating Income	-32	-33	-43	-35	-23	-14	8.67	-1.04	-16	-42	-68	-85	-97	-80	-73	-65	-55	-60	-40	-28	-20	-12	-6.54	-0.90	7.43	8.69	7.33	9.48	2.20	-1.07	-3.84
Interest Expense	0.38	0.20	0.09	0.15	0.33	0.53	0.58	0.43	0.23	0.02	0.01	0.01	0.02	0.02	0.02	0.01	0.01	0.00	0.00	0.40	1.10	1.87	2.63	3.01	3.39	4.31	4.57	4.46	3.94	2.77	2.27
Interest & Investment Income	11	11	12	12	13	13	13	13	12	11	11	9.78	8.30	6.27	3.97	1.71	0.44	0.09	0.07	0.07	0.07	0.08	0.37	0.63	0.62	0.59	0.31	0.04	0.04	0.04	0.02
Other Non-Operating Income	-0.45	-0.30	0.14	0.05	0	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	-2.71	-2.90	-2.93	-3.18	-0.51	-0.28	-0.27
Asset Impairment Charges	–	–	–	–	–	–	0	0	0	0	0	0	0	0	0	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.21	-4.82	-5.36	-6.68	-0.78	2.85	3.32	5.06	-0.92	0.13	0.10	0.12	0.09	-1.89	-1.77	-11	-11	-8.59	-8.72	0.09	0.09	0.08	0.08	0.07	0.07	0.07	0.07	0.01	0.01	0.01	0.01
Net Income	-19	-13	-24	-12	-9.47	-5.07	18	6.08	-3.10	-31	-57	-76	-89	-72	-67	-53	-44	-52	-31	-30	-23	-15	-10	-3.34	7.10	7.21	5.28	7.09	-2.21	-4.10	-6.37
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-15	-10	-3.34	6.79	5.90	2.99	3.80	-6.20	-8.02	-10
EPS (Basic)(per share)	-0.66	-0.43	-0.83	-0.42	-0.32	-0.16	0.66	0.21	-0.13	-1.15	-2.14	-2.84	-3.35	-2.71	-2.58	-2.05	-1.75	-2.04	-1.24	-1.22	-0.98	-0.71	-0.54	-0.16	0.50	-0.47	0.35	-0.35	-3.11	-4.21	-5.33
EPS (Diluted)(per share)	-0.66	-0.44	-0.83	-0.46	-0.36	-0.20	0.62	0.20	-0.14	-1.15	-2.14	-2.84	-3.35	-2.71	-2.58	-2.05	-1.75	-2.04	-1.24	-1.22	-0.98	-0.71	-0.54	-0.17	0.11	-0.86	-0.21	-1.84	-4.22	-5.32	-5.33
Shares Outstanding (Basic, Weighted)(shares)	30	29	29	29	28	28	28	28	27	27	27	27	27	26	26	26	26	25	25	24	23	21	19	–	–	–	–	4.69	1.97	1.91	1.91
Shares Outstanding (Diluted, Weighted)(shares)	30	29	29	29	30	29	29	28	28	27	27	27	27	26	26	26	26	25	25	24	23	21	19	–	–	–	–	5.07	1.97	1.91	1.91
EBITDA	-17	-18	-2.04	7.83	19	29	25	12	-2.67	-29	-56	-73	-85	-69	-62	-56	-48	-55	-37	-26	-19	–	-6.07	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 77.3%
Operating margin: -9.0%
Net margin: -5.4%
Return on equity, FY2025: -5.2%

Financial strength

Current ratio: 6.04
Debt to equity: 0.02
Debt to assets: 1.8%
Cash to current liabilities: 109.9%

Valuation

P/E ratio: –
Price to sales: 2.74
Price to book: 2.08
Dividend yield: 0.00%